These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

484 related articles for article (PubMed ID: 26602577)

  • 1. A Comparison of Brunt's Criteria, the Non-Alcoholic Fatty Liver Disease Activity Score (NAS), and a Proposed NAS Scoring that Includes Fibrosis in Non-Alcoholic Fatty Liver Disease Staging.
    Santiago-Rolón A; Purcell D; Rosado K; Toro DH
    P R Health Sci J; 2015 Dec; 34(4):189-94. PubMed ID: 26602577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
    Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
    APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the chilean population.
    Arab JP; Hernández-Rocha C; Morales C; Vargas JI; Solís N; Pizarro M; Robles C; Sandoval D; Ponthus S; Benítez C; Barrera F; Soza A; Riquelme A; Arrese M
    Gastroenterol Hepatol; 2017; 40(6):388-394. PubMed ID: 28359548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of the non-alcoholic fatty liver disease activity score.
    Hjelkrem M; Stauch C; Shaw J; Harrison SA
    Aliment Pharmacol Ther; 2011 Jul; 34(2):214-8. PubMed ID: 21585409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and risk factors for biopsy-proven non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in a prospective cohort of adult patients with gallstones.
    García-Monzón C; Vargas-Castrillón J; Porrero JL; Alonso MT; Bonachía O; Castillo MJ; Marcos A; Quirós E; Ramos B; Sánchez-Cabezudo C; Villar S; Sáez A; Rodríguez de Cía J; del Pozo E; Vega-Piris L; Soto-Fernández S; Lo Iacono O; Miquilena-Colina ME
    Liver Int; 2015 Aug; 35(8):1983-91. PubMed ID: 25708133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between triglyceride glucose-body mass index and the staging of non-alcoholic steatohepatitis and fibrosis in patients with non-alcoholic fatty liver disease.
    Zhang F; Han Y; Wu Y; Bao Z; Zheng G; Liu J; Li W
    Ann Med; 2024 Dec; 56(1):2409342. PubMed ID: 39348274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The comparison of scoring scales for liver biopsy assessment in morbidly obese patients undergoing bariatric surgery.
    Ziolkowski A; Wylezol M; Kukla M; Zwirska-Korczala K; Berdowska A; Pardela M; Gabriel A
    Obes Surg; 2005 Oct; 15(9):1309-14. PubMed ID: 16259893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum adipokines might predict liver histology findings in non-alcoholic fatty liver disease.
    Jamali R; Razavizade M; Arj A; Aarabi MH
    World J Gastroenterol; 2016 Jun; 22(21):5096-103. PubMed ID: 27275102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progression of liver disease in non-alcoholic fatty liver disease: a prospective clinicopathological follow-up study.
    Chan WK; Ida NH; Cheah PL; Goh KL
    J Dig Dis; 2014 Oct; 15(10):545-52. PubMed ID: 25060399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of NAFLD and fibrosis in obese patients - a comparison of histological and clinical scoring systems.
    Schmitz SM; Kroh A; Ulmer TF; Andruszkow J; Luedde T; Brozat JF; Neumann UP; Alizai PH
    BMC Gastroenterol; 2020 Aug; 20(1):254. PubMed ID: 32758151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of non-invasive parameters of non-alcoholic steatohepatitis and liver fibrosis in daily practice--an exploratory case-control study.
    Dvorak K; Stritesky J; Petrtyl J; Vitek L; Sroubkova R; Lenicek M; Smid V; Haluzik M; Bruha R
    PLoS One; 2014; 9(10):e111551. PubMed ID: 25350286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-alcoholic fatty liver disease in pediatric type 2 diabetes: Metabolic and histologic characteristics in 38 subjects.
    Newfield RS; Graves CL; Newbury RO; Schwimmer JB; Proudfoot JA; Say DS; Feldstein AE
    Pediatr Diabetes; 2019 Feb; 20(1):41-47. PubMed ID: 30467936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low clinical relevance of the nonalcoholic fatty liver disease activity score (NAS) in predicting fibrosis progression.
    Ekstedt M; Franzén LE; Mathiesen UL; Kechagias S
    Scand J Gastroenterol; 2012 Jan; 47(1):108-15. PubMed ID: 22126450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study.
    Newsome PN; Sasso M; Deeks JJ; Paredes A; Boursier J; Chan WK; Yilmaz Y; Czernichow S; Zheng MH; Wong VW; Allison M; Tsochatzis E; Anstee QM; Sheridan DA; Eddowes PJ; Guha IN; Cobbold JF; Paradis V; Bedossa P; Miette V; Fournier-Poizat C; Sandrin L; Harrison SA
    Lancet Gastroenterol Hepatol; 2020 Apr; 5(4):362-373. PubMed ID: 32027858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The HAALT Non-invasive Scoring System for NAFLD in Obesity.
    Sheth H; Bagasrawala S; Shah M; Ansari R; Olithselvan A; Lakdawala M
    Obes Surg; 2019 Aug; 29(8):2562-2570. PubMed ID: 31016455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD).
    Verma S; Jensen D; Hart J; Mohanty SR
    Liver Int; 2013 Oct; 33(9):1398-405. PubMed ID: 23763360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histologically proven non-alcoholic fatty liver disease and clinically related factors in recipients after liver transplantation.
    Kim H; Lee K; Lee KW; Yi NJ; Lee HW; Hong G; Choi Y; You T; Suh SW; Jang JJ; Suh KS
    Clin Transplant; 2014 May; 28(5):521-9. PubMed ID: 24579874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive factors of non-alcoholic steatohepatitis: relationship with metabolic syndrome.
    Aller R; Izaola O; Ruiz-Rebollo L; Pacheco D; de Luis DA
    Nutr Hosp; 2015 Jun; 31(6):2496-502. PubMed ID: 26040357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease.
    Nascimbeni F; Bedossa P; Fedchuk L; Pais R; Charlotte F; Lebray P; Poynard T; Ratziu V;
    J Hepatol; 2020 May; 72(5):828-838. PubMed ID: 31862486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growing burden of nonalcoholic fatty liver disease in Turkey: A single-center experience.
    Yılmaz Y; Kanı HT; Demirtaş CÖ; Kaya E; Sapmaz AF; Qutranji L; Alkayyali T; Batun KD; Batman M; Toy B; Çiftaslan A
    Turk J Gastroenterol; 2019 Oct; 30(10):892-898. PubMed ID: 31258138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.